Sequestration of ass in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Oct 13, 2005
app pub date -
May 24, 2005
filing date -
Dec 17, 2001
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present invention describes a method of administering an A.beta.-binding agent or drug which has affinity for amyloid beta (A.beta.) in the periphery (blood) and reducing A.beta. levels in the brain without the need for the agent or drug to enter the brain itself. The A.beta.-binding agents utilized in the methods of the invention are preferably non-immunomodulating agents (e.g., antigenic peptides or antibodies) and bind to A.beta. in the periphery, or blood. Such compounds do not significantly cross the blood/brain barrier, and yet they lower amyloid (A.beta.) levels in the brain, thereby serving as safer, therapeutic and prophylactic treatments against diseases associated with A.beta. in the brain, e.g., Alzheimer's Disease and amyloid angiopathy, as well as against other AD-related amyloidoses.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully